In the Phase 2 trial, the most common side effects were gastrointestinal, the same pattern seen with semaglutide and tirzepatide
Compounds appearing in fewer than 20% of Alabama listings including MOTS-c, Tesamorelin, MK-677 are less commonly disclosed
common reactions include transient pain, erythema, or pruritus at the administration site, along with mild diarrhea, headache, or nausea in a minority of recipients
This is largely driven by the GLP-1 receptor agonism
Celebrities and influencers such as Oprah Winfrey, Elon Musk and Rachael Knight Guellete are confirmed to be using GLP-1s and will often be seen promoting these products
Thirty-five-week-old MC4R mice were randomly divided into four groups with no blinding at one day before drug treatment, vehicle (saline, s.c.), semaglutide (0.5 mg/kg, s.c.), tirzepatide (0.05 mg/kg, s.c.), and retatrutide (0.05 mg/kg, s.c.) based on amounts of food intake from day 25 before drug treatment, body weight at day 2 before treatment, and fat mass at one day before treatment